Teena West

Increased Plasma Natriuretic Peptide Levels Reflect Symptom Onset in Aortic Stenosis

Background—The onset of symptoms is a critical point in the natural history of aortic stenosis and the cardinal indication for valve replacement. This study assessed the associations between natriuretic peptide levels, disease severity, and cardiac symptoms in aortic stenosis. Methods and Results—Seventy-four patients with isolated aortic stenosis underwent independent assessment of symptoms, transthoracic echocardiography, and measurement of plasma levels of atrial natriuretic peptide, brain natriuretic peptide (BNP), and N-BNP. Natriuretic peptide levels were also measured in 100 clinically normal control subjects. The aortic valve area was smaller in symptomatic patients (n=45) than in asymptomatic patients (n=29; mean, 0.71±0.23 cm2 and 0.99±0.31 cm2, respectively;P <0.0001). Plasma natriuretic peptide levels were higher in symptomatic patients than in asymptomatic patients (for N-BNP: median, 112 versus 33 pmol/L; interquartile range, 70 to 193 versus 16 to 58 pmol/L, respectively;P =0.0002). After adjustment for age, sex, serum creatinine, aortic valve area, and left ventricular ejection fraction, N-BNP levels were 1.74 times higher (95% confidence interval, 1.12 to 2.69) for symptomatic than asymptomatic patients with aortic stenosis (P =0.014). Natriuretic peptide levels increased with the New York Heart Association class (for N-BNP median values were 13, 34, 105, and 202 pmol/L for normal control subjects, class I, class II, and class III/IV patients, respectively; interquartile ranges for the same patients were 8 to 21, 16 to 58, 57 to 159, and 87 to 394 pmol/L;P <0.0001). Similar associations were observed for BNP and atrial natriuretic peptide. Conclusions—Plasma natriuretic peptide levels are elevated in symptomatic patients with aortic stenosis. Measurement of natriuretic peptides may complement clinical and echocardiographic evaluation of patients with aortic stenosis.

Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation

OBJECTIVESnThis paper will describe associations between plasma natriuretic peptide levels and the severity and symptoms of mitral regurgitation (MR).nnnBACKGROUNDnA biochemical test that assisted grading of the severity of MR and the interpretation of symptoms would be of clinical value.nnnMETHODSnForty-nine patients with isolated MR and left ventricular (LV) ejection fractions (EFs) of >55% underwent transthoracic echocardiography, assessment of symptoms, and measurement of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and its amino-terminal portion, N-BNP.nnnRESULTSnThe level of each natriuretic peptide rose with increasing severity of MR and with increases in left atrial (LA) dimensions (p < 0.001 for all comparisons), but no significant correlation existed between any natriuretic peptide and the LV dimensions or EF. Natriuretic peptide levels were higher in symptomatic MR (n = 16, BNP geometric mean 16.9 [95% confidence interval (CI) 13.3 to 21.4] pmol/l) compared with asymptomatic MR (n = 33, BNP 7.1 [95% CI 6.0 to 8.4] pmol/l, p < 0.001), and higher in asymptomatic MR than in normal controls (n = 100, BNP 5.3 [95% CI 4.8 to 5.8] pmol/l, p < 0.0001). These differences were similar for N-BNP and ANP and remained statistically significant (p < 0.05) after adjustment for echocardiographic measures of LV function and severity of MR. Both the sensitivity and the specificity for symptoms for the natriuretic peptides (area under receiver-operator characteristic curve for BNP = 0.90, N-BNP = 0.89, ANP = 0.89) were similar to the MR score (0.88) and greater than for LA dimension (0.81), vena contracta width (0.82), and LV end-systolic dimension (0.63).nnnCONCLUSIONSnPlasma natriuretic peptides levels increase with the severity of MR and are higher in symptomatic compared to asymptomatic patients, even when LV EF is normal.

Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)

Objective The aim of this study was to assess the association between maximum daily atrial fibrillation (AF) burden and risk of ischaemic stroke. Background Cardiac implanted electronic devices (CIEDs) enhance detection of AF, providing a comprehensive measure of AF burden. Design, setting, and patients A pooled analysis of individual patient data from five prospective studies was performed. Patients without permanent AF, previously implanted with CIEDs, were included if they had at least 3 months of follow-up. A total of 10 016 patients (median age 70 years) met these criteria. The risk of ischaemic stroke associated with pre-specified cut-off points of AF burden (5 min, 1, 6, 12, and 23 h, respectively) was assessed. Results During a median follow-up of 24 months, 43% of 10 016 patients experienced at least 1 day with at least 5 min of AF burden and for them the median time to the maximum AF burden was 6 months (inter-quartile range: 1.3–14). A Cox regression analysis adjusted for the CHADS2 score and anticoagulants at baseline demonstrated that AF burden was an independent predictor of ischaemic stroke. Among the thresholds of AF burden that we evaluated, 1 h was associated with the highest hazard ratio (HR) for ischaemic stroke, i.e. 2.11 (95% CI: 1.22–3.64, P = 0.008). Conclusions Device-detected AF burden is associated with an increased risk of ischaemic stroke in a relatively unselected population of CIEDs patients. This finding may add to the basis for timely and clinically appropriate decision-making on anticoagulation treatment.

DEVICE DETECTED ATRIAL FIBRILLATION AND RISK FOR STROKE: AN ANALYSIS OF MORE THAN 10,000 PATIENTS FROM THE SOS AF PROJECT (STROKE PREVENTION STRATEGIES BASED ON ATRIAL FIBRILLATION INFORMATION FROM IMPLANTED DEVICES)

Cardiac implanted electronic devices (CIEDs) enhance detection of atrial fibrillation (AF), providing a comprehensive measure of AF burden.nnTo assess the association between maximum daily AF burden and risk of stroke.nnA pooled analysis of individual patient data from 3 prospective studies was

Stent longitudinal flexibility : A comparison of 13 stent designs before and after balloon expansion

Longitudinal flexibility is an important property of coronary stents, facilitating delivery and allowing the expanded stent to conform to vessel contour. Subjective descriptions of flexibility abound, but there are few independent quantitative data to aid stent selection. A three‐point bend test was employed to measure stiffness, the reciprocal of flexibility, for 13 stent designs in the unexpanded (bare) state, then after expansion with a 3.5‐mm balloon. For eight of the designs, stiffness of the proprietary stent/balloon delivery system was also measured. In the unexpanded state, there was a wide spread of stiffness, which ranged from 0.5 ± 0.2 to 91.5 ± 10.0 g force/mm, depending on design. Stiffness was least for the coil (Wiktor and Crossflex) and hybrid (AVE GFX and Bard XT) designs. The MultiLink was the most flexible and the Crown the stiffest of the slotted tube designs. All stents became stiffer upon expansion. For most manufacturer‐mounted stents, the delivery balloon was the main determinant of stent/balloon delivery system stiffness. Manufacturer‐mounted stent profile ranged from 1.15 ± 0.11 mm for the Jostent to 1.53 ± 0.05 mm for the MultiLink system. Independent quantitative assessment of characteristics such as flexibility and profile should aid rational comparison of stent designs. Cathet. Cardiovasc. Intervent. 50:120–124, 2000.

Use of Monogen for pediatric postoperative chylothorax

BACKGROUNDnPostoperative chylothorax is a potentially serious complication of pediatric cardiac surgery. The purpose of this study was to report the use of Monogen enteral formula for the management of pediatric postoperative chylothorax.nnnMETHODSnA retrospective, single-institution 2-year study of all patients with a diagnosis of postoperative chylothorax was conducted. Chylothorax was diagnosed in 25 patients after a total of 535 cardiac operations in children younger than 10 years, for an incidence of 4.7%. Eighteen patients had been given Monogen, an enteral low long-chain triglyceride formula, as initial treatment. Six had been given total parenteral nutrition. The following variables were related to outcome and response to Monogen: age, sex, weight, underlying condition, type of surgery, interval between surgery and chylothorax diagnosis, duration and daily volume of chyle leak, central venous pressure, residual lesions, and weight loss.nnnRESULTSnEnteral feeding with Monogen was successful for 14 of 18 patients with a response to treatment evident by the end of the third day. No variables predicted which patients would respond to Monogen. Body weight was maintained or increased in 14 of the 17 surviving patients taking Monogen. A return to normal diet at 4 +/- 1 weeks from the day of pleural drain removal did not result in recurrent chylothorax.nnnCONCLUSIONSnA trial of Monogen is recommended as initial treatment for postoperative chylothorax unless enteral feeding is contraindicated.

Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation

In 40 patients with chronic moderate to severe aortic regurgitation, brain natriuretic peptide, N-brain natriuretic peptide, and atrial natriuretic peptide were higher in symptomatic patients compared with asymptomatic patients after adjustment for age, gender, and ejection fraction, but each natriuretic peptide correlated weakly with echocardiographic measures of left ventricular size and function. In patients with chronic aortic regurgitation, measurement of natriuretic peptide levels may provide information on left ventricular function in addition to echocardiography.

A randomized study of direct coronary stent delivery compared with stenting after predilatation: The NIR future trial

This randomized trial compared a strategy of direct stenting without predilatation (n = 39) with conventional stenting with predilatation (n = 42) in patients with suitable lesions in native vessels ≥ 2.5‐mm diameter to be covered by either a 9‐ or 16‐mm‐length NIR Primo stent. Equipment cost [mean (median) ± SD] was less in those with direct stenting [

Bacteriological Outcome after Valve Surgery for Active Infective Endocarditis: Implications for Duration of Treatment after Surgery

1,199 (979) ± 526] than in those with predilatation [

Percutaneous closure of patent foramen ovale.

1,455 (1,285) ± 401, P < 0.001]. There was no significant difference in contrast use or fluoroscopy time. Procedural time was shorter in the direct stenting group. The clinical outcome at 1 month was satisfactory in both groups. In selected patients, a strategy of direct stenting is feasible, costs less, and is quicker to perform than the conventional strategy of stenting following predilatation. Cathet. Cardiovasc. Intervent. 50:377–381, 2000.